Great presentation.
Let's hope it gets the traction it deserves. |
I thought Anne-Sophie was better at answering the questions than the presentation… Giod to hear there’s a lot more data coming… Should be out relatively quickly too I would hope. |
CTdna is looking back, as are produced also by dying cancer cells, while CTC's are looking forward as they represent where the cancer is and might metastasise |
Well 2 questions with interesting answers..… Lots more data to come it would appear… 1000 samples awaiting analysis… Bigger cohorts, different tumour sites… And biomarkers/druggable targets have been found on CTCs but not on ctDNA…. |
Very significant breakthroughs as we know.
Now focus needs to be fully commercialising it and ensure a reasonable price when likely equity dilution comes. |
CtDNA ...past data.CTC...forward looking data. How will it progress.Ctcs are a huge source of biomarkers. Parsotix is the first FDA cleared medical device. |
CtCs bring the most potentialAngles Parsotix system is the CTC benchmark |
Angle are in the European liquid biopsy Society |
"illumina and Angle are partners"
That blows the nonsense PATT was spilling out of the water. |
webinar started |
Worth a look..
'...as it revealed strong sales of cancer drugs helped lift revenues higher.' |
"We expect to see a lot of ongoing commercial activity as a result"
Time to prove it guys. |
They will have some sort of collaboration agreement in place already. Low risk for Illumina, as they can gauge interest in joint CTC and CTdna, before they move.
Excellent access to a market with the market leader could be the game changer. Surely Illumina will want to own outright? Interesting times. |
And how would they exactly do that ?
Without diluting us all yet again. |
At a premium of course. |
goosed, I was thinking the very same thing. Between 5% and 10% would do nicely. |
At this juncture, I wouldn't be at all surprised to see Illumina taking a minority stake in Angle in the not too distant future. Particularly as both parties have been communicating the latest results in Lung Cancer to a commercial audience.
An independent Angle would continue to develop using the existing team but benefit from the considerable commercial resources that Illumina have at their disposal. Pure speculation of course but perhaps not so outlandish. |
"Expecting a lot of ongoing commercial activity as a a result" (In ref to Illumina)
Edit: Illumina machines are in over 10,000 labs world wide. Actually it's 22,000 instal base (some have more than one I guess)
$4bn revenue. Note "M&A focused on bolt on size key strategic enablers. " I think that's us |
fresh video/podcast @11am
Reminder today @ 4 o clock !!!!
Date & TimeFeb 6, 2025 16:00 in
DescriptionLiquid biopsy analytes including circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) represent important minimally invasive biomarker sources for molecular profiling as a step towards realizing precision oncology.
In this webinar, Anne-Sophie Pailhes-Jimenez will present dual analysis data from samples taken from lung cancer patients using Parsortix system by ANGLE. Targeted next-generation sequencing (NGS) on the NextSeq 2000 sequencer was performed and revealed mutations identified exclusively on CTCs compared to cfDNA. Overall, dual analysis of liquid biopsy analytes may hold potential to capture a more comprehensive picture of tumour heterogeneity and ultimately inform personalised cancer care |
Nice, clear video AN interview on the Angle website, explaining today's novel findings using the Parsortix system demonstrating the role of CTC:B cell clusters in driving cancer progression - complete with closing cheesy grin...... |
Already registerered… I hope Anne-Sophie is well drilled and the presentation slick…
The regulatory RNSs are sometimes frustrating but the way the indications are expanding with this fundamental research completed by leaders in their fields illustrates the potential multiple indications in the research space, some of which will translate to the prognostic/predictive markers which will really drive mass adoption. Research adoption is a lot about networking and achieving critical mass by persuading others to jump on the bandwagon… With the best solution.
And with that regulatory RNS there was a classic suck in the sellers… So we’ve got some stock for the buyers later… |
I truly hope and pray that the developments in the past few weeks come to fruition through long and medium term revenue contracts. If , as previously, this all turns to dust then sadly I really fear we are drinking in the last chance saloon |
Register to chat with like-minded investors on our interactive forums.
Hot Features
Premium
